Recombinant antibody phage display technology is a vital tool that facilitates identification of specific binding molecules to a target enabling the rapid generation and selection of high affinity, fully human, or mouse antibody product candidates essentially directed towards disease target appropriate for antibody therapy. In this study, a recombinant single-chain Fv antibody fragment (scFv) A11 was isolated from immune spleen cells obtained from mice immunized with inactivated rabies virus (Pasteur strain) using standard methodology and was characterized for its specificity towards the rabies virus glycoprotein. Epitope mapping using peptide libraries and truncated glycoprotein polypeptides suggested that A11 bound to the antigenic site II of rabies glycoprotein against which a majority of rabies virus neutralizing antibodies are directed. The use of the above technology could, therefore, allow development of scFvs with different specificities against the rabies glycoprotein as an alternative to the more cumbersome protocols used for the development of monoclonal antibodies.
CITATION STYLE
Aavula, S. M., Nimmagadda, S. V., Biradhar, N., Sula, S., Chandran, D., Lingala, R., & Villuppanoor, S. A. (2011). Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein. Biotechnology Research International, 2011, 1–11. https://doi.org/10.4061/2011/652147
Mendeley helps you to discover research relevant for your work.